Acta paediatrica (Oslo, Norway : 1992) · 2026
Safety and Clinical Outcomes of High- Versus Low-Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Łyżwa Klementyna, Chojnowska-Wójtowicz Magdalena, Zagórska Wioletta, Kulus Marek, Grzela Katarzyna
Аннотация
AIM: To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy.
METHODS: This prospective study enrolled 44 children aged 4-17 years with confirmed peanut allergy. Following dose escalation, participants were allocated to receive either 150 or 300 mg of peanut protein daily for 8 weeks. Oral food challenges (OFCs) were conducted before and after OIT. The primary endpoint was the proportion of participants tolerating ≥ 300 mg of peanut protein post-treatment. Secondary outcomes included changes in immunologic markers (skin prick tests wheal size, sIgE, IgG4) and safety.
RESULTS: Of the 44 enrolled children, 33 (75.0%) completed the full protocol. The primary outcome was achieved in 73.9% of the 150 mg group and 71.4% of the 300 mg group (p = 0.853). Both regimens were associated with reductions in immunological parameters. Adverse events were mainly mild to moderate.
CONCLUSION: Peanut OIT using either 150 mg or 300 mg maintenance doses was associated with increased tolerance thresholds and immunological changes in highly allergic children. These findings support the feasibility of OIT in real-world clinical settings while highlighting the need for further multicentre research to determine optimal dosing strategies.
METHODS: This prospective study enrolled 44 children aged 4-17 years with confirmed peanut allergy. Following dose escalation, participants were allocated to receive either 150 or 300 mg of peanut protein daily for 8 weeks. Oral food challenges (OFCs) were conducted before and after OIT. The primary endpoint was the proportion of participants tolerating ≥ 300 mg of peanut protein post-treatment. Secondary outcomes included changes in immunologic markers (skin prick tests wheal size, sIgE, IgG4) and safety.
RESULTS: Of the 44 enrolled children, 33 (75.0%) completed the full protocol. The primary outcome was achieved in 73.9% of the 150 mg group and 71.4% of the 300 mg group (p = 0.853). Both regimens were associated with reductions in immunological parameters. Adverse events were mainly mild to moderate.
CONCLUSION: Peanut OIT using either 150 mg or 300 mg maintenance doses was associated with increased tolerance thresholds and immunological changes in highly allergic children. These findings support the feasibility of OIT in real-world clinical settings while highlighting the need for further multicentre research to determine optimal dosing strategies.